Atlas Trials

Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)

Clinical trial NCT04093505 · TERMINATED

Trial details

NCT number
NCT04093505
Sponsor
University Hospital Heidelberg
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Acute Myeloid Leukemia
Start date
2021-04-01
Primary completion
2022-06-15
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.